MyChoices Project, an intervention trial testing the effect of a decision aid on knowledge and decision-making outcomes among women with breast cancer who are seeking complementary therapies to manage their menopausal symptoms. Dugald Seely, ND, MSc (Ottawa Integrative Cancer Centre) reviewed the process of working through a series of systematic reviews, including the use of meta-analysis on specific therapies relevant to integrative oncology, and discussed the limitations and challenges of synthesizing, sharing, and using this type of evidence. Michelle Kohn, MBBS, BSc, FRCP (LOC: Leaders in Oncology Care) discussed barriers to knowledge uptake in integrative oncology using her professional experience in directing the Living Well Programme in London, United Kingdom.
A conference highlight was a joint plenary session presented by SIO and the American Society of Preventive Oncology (http://www.aspo.org), which was designed to foster collaborative bridges between research organizations. This session featured presentations on challenges and recruitment and retention strategies in behavior change research (Wendy Demark-Wahnefried, PhD, RD, University of Alabama at Birmingham); a review of mind-body interventions (Anita Kinney, PhD, University of New Mexico); a discussion of study design issues in diet and physical activity research (Karen Basen-Enquist, PhD, MPH, MD Anderson Cancer Center); and survivorship research resources, including the Women's Health Initiative Cancer Survivor Cohort (Electra Paskett, PhD, Ohio State University Cancer Center).
A third plenary highlighted data on mind-body interventions designed to reduce stress and improve social support for cancer patients and survivors. In this symposium, Susan Lutgendorf, PhD (University of Iowa) provided an overview of recent advances in our ability to study and detect stress influences in cancer markers and disease progression. Linda Carlson, PhD, CPsych (University of Calgary and Tom Baker Cancer Centre) presented an example of clinical research on mindfulness-based and supportive interventions that affect a range of potentially important biomarkers in breast cancer survivors. Joanne Stephen, PhD (British Columbia Cancer Agency) discussed the potential of disseminating mind-body interventions through the Internet, with reference to research on an innovative pan-Canadian psychosocial intervention "CancerChatCanada."
Other highlights from plenary sessions included presentation of data on the potential role of the microbiome and probiotics for chemoprevention and treatment of cancer, including clinical trial results describing the use of probiotics as a ) versus standard of care (SC) in 32 women for depression, and in 57 women with anxiety who reported ≥8 at baseline on the Hospital Anxiety Depression Scale (HADS) depression or anxiety subscales, as appropriate, and who were from an ongoing randomized clinical trial on acupressure for persistent cancer-related fatigue in BCS. Analyses of variance (ANOVA) were performed on mean differences of changes (baseline to week 6) in anxiety and depression subscales by group.
Results: There was a significant decrease in depression (P = .02 vs SA; P = .06 vs SC) but not in anxiety (P = .36 vs SA; P = .46 vs SC) in the RA group compared with either SA or SC. This represents a −47% mean decrease from baseline in depression in the RA group versus −16% in the SA group and 22% in the SC group, and on average a movement from being borderline abnormal on the HADS depression subscale at baseline (9.2 ± 0.98, 0-21 point scale) to normal (4.9 ± 2.7) at 6 weeks. Conclusion: In this preliminary analysis, self-administered RA engenders a greater antidepressive response as compared with either SA or SC in fatigued BCS. These findings should be interpreted with caution given our small sample size. More rigorous studies are recommended. Our preliminary findings suggest that electro-acupuncture may have the potential to address a cluster of symptoms in breast cancer survivors receiving AIs. The similar treatment effects between the electro and sham groups suggest that a large component of acupuncture effect is mediated through the process of acupuncture delivery rather than the specificity of needling techniques.
of defense against developing neoplasms. We previously showed both tumor reduction and immune-enhancement in leukemia cell-injected DBA/2 mice given a proprietary extract of North American ginseng (CVT-E002) daily, via the diet. The extract is in the marketplace as Cold FX. Methods: Elderly, female C3H/HeN mice were used because they are prone to the development of assorted cancers, predominant among which are breast cancers. A homogenized mixture of powdered standard mouse chow containing CVT-E002 (80 mg/6 g chow/day/mouse), was fed for 11 months, from age 22 months, after which half the mice were euthanized (age 33 months). The chow of parallel control mice contained no CVT-E002. The spleens (SPL) and bone marrow (BM) were removed and assayed for their content of NK cells and lymphocytes. The remaining half of the CVT-E002-fed mice were placed on the control diet at 11 months and left to assess life span. Results: In mice consuming CVT-E002 from 22 to 33 months, the absolute numbers of NK cells in their SPL and BM were elevated over control (P < .0004 and P < .0001, respectively) as were the absolute numbers of lymphocytes (non-NK) in both organs (P < .0001 and P < .0001, respectively). No CVT-E002-consuming mouse had any tumors at whole-body autopsy when euthanized (age 33 months) versus 100% bearing tumors (47% breast cancers) in control-diet mice. The remaining half (above) of the CVT-E002-consuming mice lived on until they were intentionally euthanized just over 4 years of ageall still tumor free. Conclusion: The results indicate (1) a profound effect of CVT-E002 in tumor resistance, (2) a significant increase in the numbers of immune cells, and (3) a strikingly long life (>4 years) in these inbred mice, equivalent to 126 human years. Abstract Background: The chemopreventive and therapeutic effects of vitamin D3 are exerted through 1α,25-(OH) 2 D3, the dihydroxy metabolite of vitamin D3. Inactivation of 1α,25-(OH) 2 D3 by cytochrome P450 3A (CYP3A) enzymes can be an important determinant of its serum and tissue levels. The purpose of the present study was to assess the potential of various medications, which are commonly used in the treatment regimens of patients with cancer (eg, abiraterone, ketoconazole, tamoxifen, taxanes) and as premedications (eg, dexamethasone, prednisone) to chemotherapy, on biotransformation of 1α,25-(OH) 2 D3 in human and mouse liver microsomes. Methods: Adult CD-1 mice were treated with vehicle (50% ethanol), dexamethasone (80 mg/kg/day) or prednisone (80 mg/kg/d) for 3 consecutive days by intraperitoneal injection. Mouse livers were used to prepare microsomes by differential ultracentrifugation. In vitro reaction mixtures contained potassium phosphate buffer, mouse or human hepatic microsomal protein (XenoTech LLC) or human recombinant CYP3A4 supersomes, NADPH, and a fixed concentration of 20 µM 1α,25-(OH) 2 D3. Reactions were initiated with NADPH after initial preincubation of microsomes with 1α,25-(OH) 2 D3 and various concentrations of abiraterone (0.2-100 µM), ketoconazole (0.05-10 µM), tamoxifen (1-100 µM), and docetaxel (0.1-1.24 µM) at 37°C. Formation of hydroxylated metabolites of 1α,25-(OH) 2 D3 were analyzed by liquid chromatography-mass spectrometry method. Results: The formation of hydroxy metabolites was significantly stimulated in hepatic microsomes from mice treated with dexamethasone compared with vehicle-and prednisone-treated group. Co-incubation of 1α,25-(OH) 2 D3 with various drugs led to up to ˜85% to 99% inhibition of formation of hydroxylated metabolites of 1α,25-(OH) 2 D3 and therefore reduced inactivation of active vitamin D3. The IC50 values (GraphPad PrismTM v4.0 software) for individual metabolites of 1α,25-(OH) 2 D3 ranged from 0.012 to 2.20 µM in human liver microsomes. Conclusions: In summary, our results suggest that premedications and co-medications administered in cancer patients can either exacerbate or inhibit the CYP3Amediated inactivation of active vitamin D3 leading to altered vitamin D homeostasis.
Preclinical

Mind-Body
Abstract 71: Disturbed Sleep in Cancer Survivors: Is There a Place for Mindfulness-Based Interventions? were lower than in the SHE group, indicating that both mind-body interventions improved sleep. Also, compared with the SHE group, the MBB group showed reductions in self-reported depression symptoms and improvements in overall levels of mindfulness, self-compassion, and well-being at postintervention. Conclusions: This study provides preliminary evidence that brief sleep-focused MBB and MM are promising interventions for sleep disturbance in cancer survivors. Integrating MBB or MM into posttreatment supportive plans should enhance care of cancer survivors with sleep disturbance. Because MBB produced additional secondary benefits, MBB may serve as a promising multipurpose intervention for posttreatment cancer survivors suffering from sleep disturbance and other comorbid symptoms. Management of sleep problems in survivors is a high priority issue that demands more attention in cancer survivorship.
Abstract
Background: We investigated the effectiveness of a braincomputer interface (LORETA neurofeedback) to manage acute onset pain and examine the neurophysiological mechanisms and localization of pain as a result of head and neck radiation. Methods: Patients undergoing head and neck radiation (n = 4 of 10 to date; male; right-handed; mean age = 53.5 years) completed baseline questionnaires and underwent a baseline electroencephalography (EEG). A second EEG was done on the first written prescription for pain medications, but before the medications were started, and a final EEG was performed at the conclusion of radiotherapy. Patients had a total of 6 LORETA neurofeedback sessions after their pain became at least a 4 on a 0 to 10 scale for 3 consecutive days. Patients were asked to rate their pain on a scale of 0 to 10 before and after each neurofeedback session. The Brief Pain Inventory (BPI), the Multidimensional Pain Inventory (MPI), and the MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) were completed at baseline and end of radiotherapy. Results: LORETA results demonstrated that (1) regions of the pain network increase in beta (13-21 Hz) activity relative to baseline (primary somatosensory cortex, dorsolateral prefrontal cortex), and other regions not associated with the pain network also increased in activity (precuneus). During LORETA neurofeedback sessions, patients could reduce activity in the pain network relative to their "painful" EEG map activity. Pain ratings also decreased from pre-to post-session (mean decrease = 2.14). Self-report data and the association between self-report and brain activity will be presented with the complete data set (n = 10). Conclusions: We were able to capture brain activity during acute pain onset and show that patients can change that brain activity to a less painful state with LORETA neurofeedback. Identification of these regions and successful EEG neurofeedback training will allow a targeted approach to acute pain management that is independent of medications. ) at baseline, and 1, 4, and 10 months after the writing sessions. Results: The mean age of participants was 58 years, and 41% were female. Participants had been diagnosed with stage I (38%), stage II (14%), stage III (18%), or stage IV (28%). After controlling for baseline levels of the outcome variables, multilevel modeling analyses revealed that participants in the EW group who had elevated depressive symptoms at baseline had worse outcomes than those in the NW group with elevated depressive symptoms at baseline. Specifically, at 1 month postintervention, participants in the EW group reported more cancer-related symptoms (MADSI; P < .01), sleep disturbances (PSQI; P < .01), and fatigue (BFI; P < .01) compared with those in the NW group. There were no group differences for those low in baseline depressive scores. Conclusions: These findings suggest that patient baseline characteristics may moderate the effectiveness of an EW program. Those with elevated depressive symptoms at study entry do not appear to benefit from an EW program and, in fact, EW may result in worse outcomes. Clinician-facilitated treatments providing more intense supportive care may be need to improve quality of life outcomes in patients with depressive symptoms.
Traditional Chinese Medicine and Acupuncture
Abstract 127: Acupuncture for Dysphagia After Chemoradiation Therapy in Head And Neck Cancer: A Pilot Randomized Sham-Controlled Trial
